|
国际站:Tocilizumab
CAS:375823-41-9
品牌:MedChemExpress (MCE)
存储条件:Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性:Tocilizumab (Anti-Human IL6R, Humanized Antibody) 是一种抗人白细胞介素 6 受体 (IL-6R) 中和抗体,可阻止 IL-6 与 IL-6R 结合,从而抑制两种经典的和转信令。 Tocilizumab (Anti-Human IL6R, Humanized Antibody) 可用于治疗类风湿性关节炎[1]。 Tocilizumab 对于严重 COVID-19(冠状病毒病)的研究非常有效[4]。 IC50 和目标:IC50:IL-6R[1]
体外:Tocilizumab(抗人 IL6R,人源化抗体)(1-100 ng/mL;24 小时、48 小时)以剂量依赖性方式抑制细胞增殖(生长速率),HACM 的生长速率几乎完全降低 100 ng /mL tocilizumab[2].Tocilizumab(抗人 IL6R,人源化抗体)(0.001-10,000 μg/ml;2 天)抑制 Ba/F3-gp130-IL-6R 细胞用 hIL-6 刺激增殖,IC50 为 13.5 ng/ml[1]。Tocilizumab(抗人 IL6R,人源化抗体)(1 μM ; 6 小时)在体外降低 STAT3 的磷酸化,与体内 SAS 细胞一致[3]。Tocilizumab(抗人 IL6R,人源化抗体)(1-5 μM;24 小时)用无血清培养基显着降低SAS细胞中VEGF mRNA的表达[3]。
体内:Tocilizumab(抗人 IL6R,人源化抗体)(静脉注射;1.0 mg/100 μL;每周两次,三周)减少注射了 tocilizumab 的小鼠大脑中每个转移灶的体积[2] .Tocilizumab(抗人 IL6R,人源化抗体)(腹膜内注射;100 μg/mL,每 48 小时一次;20 天)抑制 OSCC 进展并抑制肿瘤血管生成[3]。
参考文献:[1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.[2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.[3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.[4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954.
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-9-26 12:18
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社